Small molecule, indirubin-3-oxime, for prevention and treatment of bone disease

Abstract

The present invention provides a composition comprising an indirubin derivative for stimulating longitudinal bone growth. Because the composition for stimulating longitudinal bone growth according to the present invention is shown to be effective in longitudinal bone growth, it may be used not only as a composition for stimulating longitudinal bone growth, but also as a pharmaceutical composition for treating or preventing short stature, microplasia, dwarfism, or precocious puberty.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application claims priority to Korean Application No. 10-2013-0081464 filed on Jul. 11, 2013, which is incorporated herein by reference.TECHNICAL FIELD[0002]The present invention relates to a small molecule, indirubin-3-oxime, for prevention and treatment of bone disease.BACKGROUND ART[0003]The increased awareness of the importance of normal growth, as well as an increased aesthetic interest, in infants and adolescents has led to an increased public interest in height growth. In the past, height growth was thought to depend on heredity. However, it is said that the proportion to which heredity is responsible for actual height growth is only 23%, and also, depending on the care during the period of growth, sufficient height growth can be achieved. Therefore, a great deal of money is being invested, estimated to be anywhere between 4-100 million dollars, to achieve height growth within the time period in which the growth plate is not c...

AI Technical Summary

Benefits of technology

The present invention provides a food composition that includes an indirubin derivative, specifically indirubin-3′-oxime, for improving bone growth. The indirubin-3′-oxime increases the length of the tibia and the activity of the growth plate. The composition can be used to treat or prevent short stature, microplasia, dwarfism, or precocious puberty by targeting the Wnt / β-catenin signaling pathway. The compound has low toxicity and low development cost. The composition can also contain other ingredients such as sweeteners or natural carbohydrates.

Problems solved by technology

However, most of the drugs that are currently in the market simply contain nutritional supplement components, and a question remains as to the proportion of therapeutic agents for growth that produce a real effect.

Furthermore, virtually no drug has a target directly related to height growth.

However, growth hormone injection is not suitable for a child with normal hormone secretion, and instead produces side effects when used, such as hypothyroidism and hyperpituitarism.

Moreover, it is not easily accessible because of its high cost.

In addition, a recent issue concerns precocious puberty causing early closure of the growth plate, thus shortening the period of growth.

Moreover, the development cost for indirubin-3′-oxime is relatively low.

Thus, the expected effect is very large for utilizing indirubin-3′-oxime as a therapeutic agent for height growth.

It is known that the presence of an abnormality in the Wnt / β-catenin signaling pathway can cause an abnormality in bone formation (Liu et al., Cell signal., 2008).

Images